Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Potential for Improved Analgesia From Combined Medication for Superficial Pain
Brief Summary: This research study is being done to assess if a combination of medications can enhance the relief of superficial pain (pain at the surface of the skin, such as sunburn pain). The investigators also want to find out if certain genes may be linked to individual differences in experienced efficacy of pain killers. The combination of medications under investigation is diclofenac and atropine. Diclofenac has been approved by the U.S. Food and Drug Administration (FDA) to treat pain. Atropine has been approved by the FDA to treat certain types of poisoning, heartbeat problems, and other diseases but atropine is not approved to treat pain. However, atropine has been used for many years in different European countries to treat painful conditions such as stomach cramps.This research study will compare diclofenac and atropine to placebo.


Options:
A: Arm Label: Pain medication: diclofenac and atropine; Type: EXPERIMENTAL; Interventions: Drug: Diclofenac and Atropine combination drug | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Diclofenac and Atropine combination drug; Assigned to Arm(s): Pain medication: diclofenac and atropine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: HLD200 (methylphenidate); Type: EXPERIMENTAL; Interventions: Drug: HLD200 methylphenidate hydrochloride (MPH) Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HLD200 methylphenidate hydrochloride (MPH) Capsules; Assigned to Arm(s): HLD200 (methylphenidate) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 15 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg); Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride Extended Release Capsules; Assigned to Arm(s): 10 mg, 15 mg, 20 mg, 40 mg, Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Lisdexamfetamine Dimesylate; Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine dimesylate | Arm Label: Methylphenidate Hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lisdexamfetamine dimesylate; Assigned to Arm(s): Lisdexamfetamine Dimesylate | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride; Assigned to Arm(s): Methylphenidate Hydrochloride | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A